Article

Expression of the ERBB2 protein in benign and malignant salivary gland tumors.

Department of Oral Pathology, University of Göteborg, Sweden.
Genes Chromosomes and Cancer (impact factor: 3.31). 04/1991; 3(2):128-35. pp.128-35
Source: PubMed

ABSTRACT Fifty-two primary human salivary gland tumors were analyzed for expression of the p185ERBB2 protein using immunohistochemical and immunoblotting techniques. About 63% (33/52) of the tumors expressed the ERBB2 protein. The highest expression levels were detected among the carcinomas, where 32% of the tumors showed intense membrane staining in 25-100% of the tumor cells. In benign pleomorphic adenomas, the corresponding figure was only 12%. Clinical follow-up data available for 18 of the 19 patients with carcinomas suggested an association between high ERBB2 protein levels and poor prognosis as measured by recurrence of disease and/or the appearance of metastases. These results indicate that ERBB2 activation and overexpression could be an important genetic event with possible prognostic implications in a subset of malignant salivary gland tumors.

0 0
 · 
0 Bookmarks
 · 
16 Views
  • Source
    Article: Heterogeneity of erbB-2 gene amplification in bladder cancer.
    G Sauter, H Moch, D Moore, P Carroll, R Kerschmann, K Chew, M J Mihatsch, F Gudat, F Waldman
    [show abstract] [hide abstract]
    ABSTRACT: erbB-2 amplification and overexpression have been suggested as potentially useful prognostic markers in bladder cancer. We examined 141 bladder tumor specimens (45 fresh tissue samples and 96 formalin fixed tissue blocks) for erbB-2 amplification using fluorescence in situ hybridization. A dual labeling hybridization using a repetitive pericentromeric probe specific for chromosome 17 and a cosmid probe for the erbB-2 locus was performed to analyze the erbB-2 copy number in relation to chromosome 17 copy number on a cell by cell basis. Amplification (more than twice as many erbB-2 signals as centromere 17 signals per tumor) was found in 10 of 141 tumors. There was considerable heterogeneity in erbB-2 amplification. In a given tumor there was a wide range of erbB-2 copy number in amplified cells. The arrangement of erbB-2 signals in clusters in all amplified cases suggests that erbB-2 amplification occurs intrachromosomally in bladder cancer. Amplification was found only in tumors with aneusomy of chromosome 17 and was more frequent in pT2-T4 tumors than in pTa/T1 tumors. Overexpression was present without amplification in 51 tumors. All tumors with erbB-2 amplification showed erbB-2 overexpression. However, in 5 samples the proportion of cells with amplification was significantly lower than the fraction of cells with overexpression, indicating coexistence of two different mechanisms leading to overexpression in these tumors.
    Cancer Research 06/1993; 53(10 Suppl):2199-203. · 7.86 Impact Factor
  • Source
    Article: Delivery of chemo-sensitizing siRNAs to HER2+-breast cancer cells using RNA aptamers.
    Kristina W Thiel, Luiza I Hernandez, Justin P Dassie, William H Thiel, Xiuying Liu, Katie R Stockdale, Alissa M Rothman, Frank J Hernandez, James O McNamara, Paloma H Giangrande
    [show abstract] [hide abstract]
    ABSTRACT: Human epidermal growth factor receptor 2 (HER2) expression in breast cancer is associated with an aggressive phenotype and poor prognosis, making it an appealing therapeutic target. Trastuzumab, an HER2 antibody-based inhibitor, is currently the leading targeted treatment for HER2(+)-breast cancers. Unfortunately, many patients inevitably develop resistance to the therapy, highlighting the need for alternative targeted therapeutic options. In this study, we used a novel, cell-based selection approach for isolating 'cell-type specific', 'cell-internalizing RNA ligands (aptamers)' capable of delivering therapeutic small interfering RNAs (siRNAs) to HER2-expressing breast cancer cells. RNA aptamers with the greatest specificity and internalization potential were covalently linked to siRNAs targeting the anti-apoptotic gene, Bcl-2. We demonstrate that, when applied to cells, the HER2 aptamer-Bcl-2 siRNA conjugates selectively internalize into HER2(+)-cells and silence Bcl-2 gene expression. Importantly, Bcl-2 silencing sensitizes these cells to chemotherapy (cisplatin) suggesting a potential new therapeutic approach for treating breast cancers with HER2(+)-status. In summary, we describe a novel cell-based selection methodology that enables the identification of cell-internalizing RNA aptamers for targeting therapeutic siRNAs to HER2-expressing breast cancer cells. The future refinement of this technology may promote the widespread use of RNA-based reagents for targeted therapeutic applications.
    Nucleic Acids Research 03/2012; 40(13):6319-37. · 8.03 Impact Factor
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.

Keywords

19 patients
 
benign pleomorphic adenomas
 
Clinical follow-up data available
 
corresponding figure
 
ERBB2 activation
 
ERBB2 protein levels
 
genetic event
 
highest expression levels
 
immunoblotting techniques
 
intense membrane staining
 
malignant salivary gland tumors
 
p185ERBB2 protein
 
possible prognostic implications
 
primary human salivary gland tumors
 
subset
 
tumor cells
 
tumors
 

G Stenman